These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9727728)

  • 1. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo.
    Tome MB; Isaac MT
    Int Clin Psychopharmacol; 1998 Jul; 13(4):175-82. PubMed ID: 9727728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks.
    Tome MB; Isaac MT
    Int Clin Psychopharmacol; 1998 Jul; 13(4):169-74. PubMed ID: 9727727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit & cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation.
    Tome MB; Isaac MT
    Int J Psychiatry Med; 1997; 27(4):377-90. PubMed ID: 9565733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interest of the use of pindolol in the treatment of depression: review].
    Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM
    Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
    Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
    Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol.
    Tome MB; Cloninger CR; Watson JP; Isaac MT
    J Affect Disord; 1997 Jul; 44(2-3):101-9. PubMed ID: 9241570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of pindolol to potentiate antidepressant medication.
    Blier P; Bergeron R
    J Clin Psychiatry; 1998; 59 Suppl 5():16-23; discussion 24-5. PubMed ID: 9635544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial.
    Sacristán JA; Gilaberte I; Boto B; Buesching DP; Obenchain RL; Demitrack M; Pérez Sola V; Alvarez E; Artigas F
    Int Clin Psychopharmacol; 2000 Mar; 15(2):107-13. PubMed ID: 10759342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients.
    Geretsegger C; Bitterlich W; Stelzig R; Stuppaeck C; Bondy B; Aichhorn W
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):141-6. PubMed ID: 18054209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study.
    Safarinejad MR
    J Clin Psychopharmacol; 2008 Feb; 28(1):39-44. PubMed ID: 18204339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
    Dannon PN; Sasson Y; Hirschmann S; Iancu I; Grunhaus LJ; Zohar J
    Eur Neuropsychopharmacol; 2000 May; 10(3):165-9. PubMed ID: 10793318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
    Perry EB; Berman RM; Sanacora G; Anand A; Lynch-Colonese K; Charney DS
    J Clin Psychiatry; 2004 Feb; 65(2):238-43. PubMed ID: 15003079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.
    Blier P; Bergeron R
    J Clin Psychopharmacol; 1995 Jun; 15(3):217-22. PubMed ID: 7636000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
    Portella MJ; de Diego-Adeliño J; Ballesteros J; Puigdemont D; Oller S; Santos B; Álvarez E; Artigas F; Pérez V
    J Clin Psychiatry; 2011 Jul; 72(7):962-9. PubMed ID: 21034693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How long should pindolol be associated with paroxetine to improve the antidepressant response?
    Zanardi R; Artigas F; Franchini L; Sforzini L; Gasperini M; Smeraldi E; Perez J
    J Clin Psychopharmacol; 1997 Dec; 17(6):446-50. PubMed ID: 9408806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pindolol and the acceleration of the antidepressant response.
    Plenge P; Mellerup ET
    J Affect Disord; 2003 Aug; 75(3):285-9. PubMed ID: 12880941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
    Sheehan DV; Eaddy MT; Shah MB; Mauch RP
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.